Entheogens

Chicago Cannabis Leaders Launch "Green Rose Advisors" Providing Consulting Services for Cannabis Entrepreneurs in Illinois and Around the United States.

Retrieved on: 
Tuesday, August 3, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Drugs, Cannabis in Illinois

CHICAGO, Aug. 3, 2021 /PRNewswire/ --A group of Chicago cannabis leaders launched Green Rose Advisors ( https://www.greenroseadvisors.com ) a consulting firm offering expertise and resources to social equity cannabis entrepreneurs in Illinois and around the United States.

Key Points: 
  • CHICAGO, Aug. 3, 2021 /PRNewswire/ --A group of Chicago cannabis leaders launched Green Rose Advisors ( https://www.greenroseadvisors.com ) a consulting firm offering expertise and resources to social equity cannabis entrepreneurs in Illinois and around the United States.
  • Now they are offering additional consulting services and resources to help construct and operate dispensaries, craft growers and infusers as well.
  • Green Rose Advisors launched the same week the first social equity lottery was held in Illinois for 55 dispensary licenses.
  • Morreale was also co-founder and the longest serving chairman of the Medical Cannabis Alliance of Illinois (now the Cannabis Business Association of Illinois).

World's first global research institute for psychedelic therapies opens its doors

Retrieved on: 
Tuesday, August 3, 2021
Jerome Sarris, Mental health in Australia, Entheogens, Psychoactive drugs, Hallucinations, Florey Institute of Neuroscience and Mental Health, Ayahuasca, Psychedelic drug, Branches of biology, Mental Health Research Institute

MELBOURNE, Australia, Aug. 3, 2021 /PRNewswire/ -- A global team of researchers have launched a first-of-its-kind research institute that will develop psychedelic medicines to treat mental health disorders and other medical conditions.

Key Points: 
  • MELBOURNE, Australia, Aug. 3, 2021 /PRNewswire/ -- A global team of researchers have launched a first-of-its-kind research institute that will develop psychedelic medicines to treat mental health disorders and other medical conditions.
  • Psychae's Australian-based collaborating researchers are from institutions including: Swinburne University, University of Melbourne, Florey Institute of Neuroscience and Mental Health, and NICM Health Research Institute (Sydney); as well as Agriculture Victoria Research.
  • The not-for-profit Institute will advance pre-clinical and clinical studies of psychedelics including products inspired by ayahuasca (a South American psychoactive plant medicine combination).
  • Psychae Institute Co-Director Professor Jerome Sarris said, "The launch of Psychae Institute is truly a world-first milestone for research into psychedelics, with potential to transform lives.

Cannabista rewarded Standard Processing Licence for cannabis from Health Canada

Retrieved on: 
Tuesday, August 3, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Medical specialties, Clinical medicine, Medicine

LACHUTE, QC, Aug. 3, 2021 /CNW Telbec/- Cannabista Inc. ("Cannabista"), a Canadian provider of cannabis processing solutions and its affiliates (collectively "the Company"), are pleased to announce that Cannabista has been granted the Standard Processing Licence on July 30, 2021, issued by Health Canada under the Cannabis Act Regulations.

Key Points: 
  • LACHUTE, QC, Aug. 3, 2021 /CNW Telbec/- Cannabista Inc. ("Cannabista"), a Canadian provider of cannabis processing solutions and its affiliates (collectively "the Company"), are pleased to announce that Cannabista has been granted the Standard Processing Licence on July 30, 2021, issued by Health Canada under the Cannabis Act Regulations.
  • With its mass production capacity and innovative drying process, Cannabista will be operational immediately.
  • This licence positions Cannabista on the global scale as a qualified supplier, offering a full range of products, services and solutions to the cannabis industry through its outsourcing and white-label business model.
  • Our various custom-built technologies will make it possible to extract cannabis at high throughput, its refining and its formulation.

RIV Capital Sets Date for First Quarter Fiscal Year 2022 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Cannabis smoking, Health sciences, Herbalism, Medicinal plants, Psychoactive drugs, Medicine, Cannabis, Entheogens, Medical cannabis, Effects of cannabis, Government procurement in the United States

RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain.

Key Points: 
  • RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain.
  • We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry.
  • Although RIV Capital has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended.
  • RIV Capital does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

High Tide Opens New Cannabis Retail Store in Milton, Ontario

Retrieved on: 
Tuesday, August 3, 2021
Medicinal plants, Health sciences, Entheogens, Euphoriants, Herbalism, Medicine, Branches of biology, Aurora Cannabis, Cannabis in Alberta, Tilray, Cannabis, Medical cannabis

This opening represents High Tide's 89th branded retail location across Canada, and 21st in Ontario, selling recreational cannabis products and consumption accessories.

Key Points: 
  • This opening represents High Tide's 89th branded retail location across Canada, and 21st in Ontario, selling recreational cannabis products and consumption accessories.
  • High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories.
  • High Tide's retail segment features the Canna Cabana, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country.
  • Key industry investors in High Tide include Tilray Inc. (TSX: TLRY) (Nasdaq: TLRY) and Aurora Cannabis Inc. (TSX: ACB) (Nasdaq: ACB).

World's first global research institute for psychedelic therapies opens its doors

Retrieved on: 
Tuesday, August 3, 2021
Jerome Sarris, Mental health in Australia, Entheogens, Psychoactive drugs, Hallucinations, Florey Institute of Neuroscience and Mental Health, Ayahuasca, Psychedelic drug, Branches of biology, Mental Health Research Institute

MELBOURNE, Australia, Aug. 3, 2021 /PRNewswire/ -- A global team of researchers have launched a first-of-its-kind research institute that will develop psychedelic medicines to treat mental health disorders and other medical conditions.

Key Points: 
  • MELBOURNE, Australia, Aug. 3, 2021 /PRNewswire/ -- A global team of researchers have launched a first-of-its-kind research institute that will develop psychedelic medicines to treat mental health disorders and other medical conditions.
  • Psychae's Australian-based collaborating researchers are from institutions including: Swinburne University, University of Melbourne, Florey Institute of Neuroscience and Mental Health, and NICM Health Research Institute (Sydney); as well as Agriculture Victoria Research.
  • The not-for-profit Institute will advance pre-clinical and clinical studies of psychedelics including products inspired by ayahuasca (a South American psychoactive plant medicine combination).
  • Psychae Institute Co-Director Professor Jerome Sarris said, "The launch of Psychae Institute is truly a world-first milestone for research into psychedelics, with potential to transform lives.

Within Weeks of Launching in Georgia, TAAT™ is Now Sold in More Than 70 Stores Statewide

Retrieved on: 
Tuesday, August 3, 2021
Psychoactive drugs, Nicotinic agonists, Electronic cigarettes, Entheogens, Leaves, Tobacco, Cigarette, Nicotine, Menthol cigarette

The Company has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in "Original", "Smooth", and "Menthol" varieties.

Key Points: 
  • The Company has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in "Original", "Smooth", and "Menthol" varieties.
  • TAAT's base material is Beyond Tobacco, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco.
  • The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration.
  • Disclosures relating to investor relations firms retained by TAAT Global Alternatives Inc. can be found under the Company's profile on http://sedar.com .

Cannabis Genetics Complete Flight from Saskatchewan to South Africa in Mother Labs, Rascal Seed Deal

Retrieved on: 
Monday, August 2, 2021
Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Entheogens, Euphoriants, Cannabis smoking, Cannabis, Medical cannabis

SASKATOON, Saskatchewan, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mother Labs Inc. (Mother Labs) and Rascal Seed Research Laboratories Pty.

Key Points: 
  • SASKATOON, Saskatchewan, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mother Labs Inc. (Mother Labs) and Rascal Seed Research Laboratories Pty.
  • Ltd. (Rascal Seed) are happy to announce a shipment of tissue culture germplasm has been successfully received in South Africa with Health Canadas approval granted earlier this year.
  • Rascal Seed has selected premium genetics, cultivars that are 22-30% THC and +3% terpenes, and verified pest and pathogen-free, from Mother Labs curated inventory of plant material.
  • Such relationships should help lead the way in the rapidly expanding market of medical cannabis in South Africa.

Green Thumb Industries Closes Transaction to Acquire Vertically Integrated Cannabis Business in Rhode Island

Retrieved on: 
Monday, August 2, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Medical specialties, Clinical medicine

Entry into the Rhode Island cannabis market further strengthens Green Thumbs position on the East Coast, a region that has embraced the freedom for adults 21+ to choose cannabis, said Green Thumb Founder and Chief Executive Officer Ben Kovler.

Key Points: 
  • Entry into the Rhode Island cannabis market further strengthens Green Thumbs position on the East Coast, a region that has embraced the freedom for adults 21+ to choose cannabis, said Green Thumb Founder and Chief Executive Officer Ben Kovler.
  • Green Thumb Industries Inc. (Green Thumb), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
  • Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomons, incredibles, Rythm and The Feel Collection.
  • Headquartered in Chicago, Illinois, Green Thumb has 16 manufacturing facilities, licenses for 111 retail locations and operations across 14 U.S. markets.

Small Pharma Reports First Fiscal Quarter 2021 Highlights

Retrieved on: 
Friday, July 30, 2021
Amines, Psychoactive drugs, Ayahuasca, Entheogens, N,N-Dimethyltryptamine, Psychedelic drug, DMT

LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today published its first quarter results for the three months ended May 31, 2021. A full copy of the results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are to Canadian dollars.

Key Points: 
  • LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (DMT) therapies, has today published its first quarter results for the three months ended May 31, 2021.
  • In March 2021, Small Pharma successfully raised $58 million from new and existing securityholders, leading to the completion of the Reverse Takeover and listing on the TSXV in May 2021.
  • In July 2021, Small Pharma launched its DMT-assisted therapy training program to educate therapists on the process required to support treatment delivery of Small Pharmas DMT-assisted therapy clinical trials.
  • In July 2021, Small Pharma received granted status under patent number GB2585978 for its UK patent application GB2008303.6.